JERRICK PADILLA-PHU: Open Payments
NPI 1457976938 · GLENDALE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,970 in 173 payments from 45 companies in 2025. Trend: 2023 $4,512 · 2024 $4,049 · 2025 $4,970
Food & beverage: $3,970Long term medical supply or device loan: $1,000
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 21 | $1,182 |
| PFIZER INC. | 11 | $268 |
| Eisai Inc. | 11 | $230 |
| Merck Sharp & Dohme LLC | 7 | $219 |
| Janssen Biotech, Inc. | 10 | $200 |
| GlaxoSmithKline, LLC. | 7 | $192 |
| Genentech USA, Inc. | 8 | $188 |
| E.R. Squibb & Sons, L.L.C. | 9 | $167 |
| Lilly USA, LLC | 7 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $144 |
Products named: KISQALI, Lenvima, OJJAARA, KEYTRUDA, Venclexta, VERZENIO, TIVDAK, Enhertu.
Industry payments across CA — which companies pay providers there.
